Sign In
Buy URGN
$26.60
+0.0600 (+0.226%)
At Close: Jun 03, 2026
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 08'th Mar 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
08:00am, Monday, 26'th Feb 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
UroGen Pharma to Participate at Upcoming Investor Conferences
08:00am, Thursday, 01'st Feb 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
08:00am, Wednesday, 24'th Jan 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today an
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
08:00am, Wednesday, 17'th Jan 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers.
UroGen Pharma to Participate in the B. Riley Healthcare Conference
08:00am, Thursday, 11'th Jan 2024
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 08'th Dec 2023
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
Urogen Pharma Ltd (URGN) Q3 2023 Earnings Call Transcript
02:59pm, Tuesday, 14'th Nov 2023
Urogen Pharma Ltd (URGN) Q3 2023 Earnings Call Transcript
UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why
02:49pm, Friday, 18'th Aug 2023
This jump in UroGen's (URGN) stock price is attributable to positive data from two late-stage studies on bladder cancer therapy. An FDA filing for the candidate is expected next year.
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 89.61%: Read This Before Placing a Bet
11:30am, Thursday, 10'th Aug 2023
The consensus price target hints at an 89.6% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
10:46am, Thursday, 10'th Aug 2023
Urogen Pharma (URGN) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.18 per share a year ago.
Why Shares of UroGen Pharma Jumped Friday
01:41pm, Friday, 28'th Jul 2023
UroGen also announced a $120 million private placement to raise funds. The company said it could have its second marketed product as early as next year.
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
10:42am, Thursday, 16'th Mar 2023
Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
UroGen Pharma to Present at Upcoming Investor Conferences
04:00pm, Wednesday, 01'st Mar 2023
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, tod
UroGen: Struggling With Revenue And With Cash Runway
04:04am, Wednesday, 08'th Feb 2023
UroGen has an approved drug and a platform. However, there's not much growth in revenue.
